HomepageD4S • FRA
add
Daiichi Sankyo
Vorige slotkoers
€ 21,74
Dag-range
€ 21,43 - € 21,43
Jaar-range
€ 19,01 - € 37,90
Beurswaarde
46,39 mld. USD
Gem. volume
123,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (JPY) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 518,69 mld. | 21,07% |
Bedrijfskosten | 340,74 mld. | 11,02% |
Netto inkomsten | 87,15 mld. | 134,49% |
Netto winstmarge | 16,80 | 93,55% |
Winst per aandeel | — | — |
EBITDA | 101,59 mld. | 207,39% |
Effectief belastingtarief | -8,09% | — |
Balans
Totale activa
Totale passiva
| (JPY) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 639,84 mld. | -1,13% |
Totale activa | 3,46 bln. | -0,14% |
Totale passiva | 1,83 bln. | 3,39% |
Totaal aandelenvermogen | 1,62 bln. | — |
Uitstaande aandelen | 1,87 mld. | — |
Koers-boekwaardeverhouding | 0,02 | — |
Rendement op activa | 6,06% | — |
Rendement op kapitaal | 12,12% | — |
Kasstroom
Nettomutatie in liquide middelen
| (JPY) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 87,15 mld. | 134,49% |
Operationele kasstroom | 72,12 mld. | 140,65% |
Kasstroom uit beleggingen | -32,93 mld. | 48,06% |
Kasstroom uit financiering | -58,51 mld. | -1.424,12% |
Nettomutatie in liquide middelen | -42,31 mld. | -116,34% |
Vrije kasstroom | 70,33 mld. | 737,15% |
Over
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
CEO
Opgericht
1899
Hoofdvestiging
Website
Werknemers
18.726
